CN100381169C - Composite collagen eye drops - Google Patents
Composite collagen eye drops Download PDFInfo
- Publication number
- CN100381169C CN100381169C CNB2005100984251A CN200510098425A CN100381169C CN 100381169 C CN100381169 C CN 100381169C CN B2005100984251 A CNB2005100984251 A CN B2005100984251A CN 200510098425 A CN200510098425 A CN 200510098425A CN 100381169 C CN100381169 C CN 100381169C
- Authority
- CN
- China
- Prior art keywords
- collagen
- eye drops
- composite
- composite collagen
- ofloxacin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates to a kind of compound collagen protein gutta, which is the mixture of collagen protein and antibiotics. For every 100ml compound collagen gutta, there is 10-500mg collagen protein which is extracted from the tendon, 100-600mg antibiotics which include one or two kinds of the following antibiotics: ofloxacin, alficetin, tenebrimycin, while the rest is the iso-osmia, which is 5% amylaceum solution. The product has three main functions: resist bacteria and inflammation; help to keep the eyeball moist, promote the agglutination and relieve the asthenopia; be used in the treatment of the damage to the cornea, keratohelcosis, keratitis punctata, slight chemical injury to cornea as well as the thermal damage to the cornea; prevent the ophthalmia and relieve the asthenopia; prevent the cohesive property of the collagen from being diluted so as to extend the effective time of the gutta; resist the bacteria as well as promote the agglutination.
Description
Technical field
The present invention relates to Medicines.
Background technology
It is less with the collagen protein to be that raw material adds the application of eye drop aspect ophthalmic medical that an amount of antibiotic ofloxacin makes, it is of the prior art that to contain antibiotic eye drop mostly be synthetic, lack biological activity, and after the eye drop of synthetic and antibiotic combination splashes into eye, its property of medicine osmotic effect is relatively poor, property of medicine effective time is short, and use is easily developed immunity to drugs for a long time.For further improving curative effect, promote biocompatibility, be necessary to develop new eye drop kind.
Summary of the invention
The purpose of this invention is to provide a kind of composite collagen eye drops, this eye drop not only has antibacterial and anti-inflammation functions, and has the eyeball of maintenance moistening, promotes wound healing, the effect of alleviating asthenopia.This product can be used for: cornea mechanical damage, corneal ulcer, punctate keratitis, the slight chemical injury of cornea, cornea hot injury's etc. treatment; Prevent xerophthalmia and alleviate asthenopia etc.When user mode, keep the adhesiveness of collagen protein to be difficult for being diluted, prolong the effective time of medicinal liquid by tear; The dry and astringent phenomenon of eyes of avoiding using the antibiotic eye drop for a long time and producing is in the antimicrobial healing that helps promoting wound simultaneously.
The object of the present invention is achieved like this:
A kind of composite collagen eye drops has collagen protein, isotonic solution and antibiotic ofloxacin in its component, it is characterized in that: its component and component part by weight are: in every 100ml composite collagen eye drops, the collagen protein liquid hold-up is 10-500mg; The content of ofloxacin is 100-600mg, and all the other are isotonic solution;
The collagen protein of described collagen liquid is to extract from Mus tail or pig, tendon Bovis seu Bubali tendon.
Described antibiotic is an ofloxacin, and described isotonic solution is 5% glucose solution.
The present invention has following actively useful effect:
This product is to be that raw material adds the composite collagen eye drops that an amount of antibiotic is made with the collagen protein, and the effect of anti-inflammation is not only arranged, and has the eyeball of maintenance moistening, promotes wound healing, the medical effect of alleviating asthenopia.This product can be used for: cornea mechanical damage, corneal ulcer, punctate keratitis, the slight chemical injury of cornea, cornea hot injury's etc. treatment; Prevent xerophthalmia and alleviate asthenopia etc., its special efficacy is activity and the sticking property that keeps collagen protein when user mode, be difficult for being diluted, thereby eye had the good penetration medical effect and have delay antibiotic dilution time, prolong the effective time of medicinal liquid by tear; The dry and astringent phenomenon of eyes of avoiding using the antibiotic eye drop for a long time and producing is in the antimicrobial healing that helps promoting wound simultaneously.
The specific embodiment
Embodiment one:
A kind of composite collagen eye drops, the part by weight of its component and each component is: in every 100ml composite collagen eye drops, collagen content is 50mg; Antibiotic is an ofloxacin, and this ofloxacin content is 300mg, and all the other are isotonic solution, and this isotonic solution is 5% glucose solution.
This composite collagen eye drops is through following test:
Through the application of 10 wheat harvesting periods, the patient of composite collagen eye drops treatment keratopathy is totally 14 examples (23 eyes).Wherein: eyes 9 examples (18 eyes), simple eye 5 examples (5 eyes); Male's 8 examples (14 eyes), women's 6 examples (9 eyes); 12 years old to 70 years old age.Operation on cornea 3 examples (5 eyes) wherein, corneal injury 3 examples (5 eyes), punctate keratitis 3 examples (5 eyes), corneal ulcer 2 examples (3 eyes), xerophthalmia 1 example (2 eyes), hot injury's 1 example (1 eye), eye chemical injury (slightly) 1 example (2 eyes).
The average curative day of therapeutic effect corneal injury 1.4 days, punctate keratitis 6.3 days, corneal ulcer 5.5 days, chemical injury (slightly) 4.4 days, the result shows that the therapeutic effect of composite collagen eye drops is good, healing time is fast, and is without any side effects.
Embodiment two:
A kind of composite collagen eye drops, the part by weight of its component and each component is: in every 100ml composite collagen eye drops, collagen content is 100mg; Antibiotic is an ofloxacin, and this ofloxacin content is 350mg, and all the other are isotonic solution, and this isotonic solution is 5% glucose solution.
This composite collagen eye drops is through following test:
Through the application of 10 wheat harvesting periods, the patient of composite collagen eye drops treatment keratopathy is totally 14 examples (23 eyes).Wherein: eyes 9 examples (18 eyes), simple eye 5 examples (5 eyes); Male's 8 examples (14 eyes), women's 6 examples (9 eyes), 12 years old to 70 years old age.Operation on cornea 3 examples (5 eyes) wherein, corneal injury 3 examples (5 eyes), punctate keratitis 3 examples (5 eyes), corneal ulcer 2 examples (3 eyes), xerophthalmia 1 example (2 eyes), hot injury's 1 example (1 eye), eye chemical injury (slightly) 1 example (2 eyes).
The average curative day of therapeutic effect corneal injury 1.5 days, punctate keratitis 6.4 days, corneal ulcer 5.6 days, chemical injury (slightly) 4.5 days, the result shows that the therapeutic effect of composite collagen eye drops is good, healing time is fast, and is without any side effects.
Embodiment three:
A kind of composite collagen eye drops, the part by weight of its component and each component is: in every 100ml composite collagen eye drops, collagen content is 150mg; Antibiotic is an ofloxacin, and this ofloxacin content is 400mg, and all the other are isotonic solution, and this isotonic solution is 5% glucose solution.
This composite collagen eye drops is through following test:
Through the application of 10 wheat harvesting periods, the patient of composite collagen eye drops treatment keratopathy is totally 14 examples (23 eyes).Wherein: eyes 9 examples (18 eyes), simple eye 5 examples (5 eyes); Male's 8 examples (14 eyes), women's 6 examples (9 eyes); 12 years old to 70 years old age.Operation on cornea 3 examples (5 eyes) wherein, corneal injury 3 examples (5 eyes), punctate keratitis 3 examples (5 eyes), corneal ulcer 2 examples (3 eyes), xerophthalmia 1 example (2 eyes), hot injury's 1 example (1 eye), eye chemical injury (slightly) 1 example (2 eyes).
The average curative day of therapeutic effect corneal injury 1.5 days, punctate keratitis 6.4 days, corneal ulcer 5.6 days, chemical injury (slightly) 4.5 days, the result shows that the therapeutic effect of composite collagen eye drops is good, healing time is fast, and is without any side effects.
In sum, among the 42 routine patients of application, the average curative day of therapeutic effect corneal injury 1.5 days, punctate keratitis 6.4 days, corneal ulcer 5.6 days, chemical injury (slightly) 4.5 days, the result shows that the therapeutic effect of composite collagen eye drops is good, and healing time is fast, and is without any side effects.
The present invention includes a kind of preparation method of composite collagen eye drops, the concrete making step of this method is:
(1) puts to death rat → get rat afterbody → clean → sterilization;
(2) aseptic condition separates down musculus caudalis tendon → distilled water flushing tendon → acetic acid or hydrochloric acid acid molten → pepsin or papain enzymolysis → saltout → water dialysis → collagen liquid.
(3) antibiotic is added collagen liquid, mix homogeneously is made the composite collagen eye drops agent;
(4) sterile working is advanced the composite collagen eye drops fill in the eye-drop liquid bottle of strict sterilization, seals, and makes bottled composite collagen eye drops.
This product characteristics:
The constituent of this composite collagen eye drops, mainly by collagen protein, antibiotic and isotonic solution are formed, and are aqueous in use.Collagen protein has the healing of promotion wound and the effect of the work that drug slow discharges, and with the antibiotic coupling, not only has good lubrication and growth promoting function, and makes the anti-inflammation time lengthening.
Collagen protein is a kind of bioactive biomacromolecule material that possesses, it is the Main Ingredients and Appearance of extracellular matrix, the hypertrophy of pair cell, differentiation, motion and joint lubrication, wound healing, the electrolytical distribution of moisture, blood coagulation, and lubricated, the index of refraction of eyeball etc. has important facilitation, the effect that the growth of pair cell has inducing and conducts.Possess lubricating function: the unsymmetry of tropocollagen molecule structure and a large amount of hydrophilic groups because of existence, make it to have the adhesiveness and the hydrophilic of height, when cell migration, can play a part to support and lubricate, so the former eye drop of composite collagen has excellent lubricating function and health care, for xerophthalmia and asthenopic evident in efficacy.Trophism: the necessary nutrient of eye that can contain procollagen, make active reinforcement of collagen protein of eye, the integrity that keeps horny layer moisture and fibre structure improves eye cells survival environment and the metabolism that promotes eye, reaches the purpose of nutrition.
Controlled drug release: be difficult for dilutedly when composite collagen eye drops splashes into eye, can keep long drug effect.
The eye-drop liquid bottle of dress composite collagen eye drops is that medical material is made, and each collagen protein that is contained in the eye-drop liquid bottle container is identical with the content of antibiotic mixture.
Described collagen liquid is: contain collagen protein 2.01～8.01mg in the 1mL collagen liquid, all the other are aqueous solution.
This product using method: adult every day 4-6 time, 1-2 drips at every turn.The dosage that the child the uses dosage of being grown up relatively suitably reduces.
Claims (7)
1. a composite collagen eye drops has collagen protein and antibiotic ofloxacin in its component, it is characterized in that: its component and composition weight ratio are: in every 100ml composite collagen eye drops, collagen content is 10-500mg; The content of ofloxacin is 100-600mg, and all the other are isotonic solution;
Described collagen protein extracts from Mus tail, pig, tendon Bovis seu Bubali tendon.
2. composite collagen eye drops as claimed in claim 1 is characterized in that: its component and composition weight ratio are: in every 100ml composite collagen eye drops, collagen content is 50mg; The content of ofloxacin is 300mg, and all the other are isotonic solution.
3. composite collagen eye drops as claimed in claim 1 is characterized in that: its component and composition weight ratio are: in every 100ml composite collagen eye drops, collagen content is 100mg; The content of ofloxacin is 350mg, and all the other are isotonic solution.
4. composite collagen eye drops as claimed in claim 1 is characterized in that: its component and composition weight ratio are: in every 100ml composite collagen eye drops, collagen content is 150mg; The content of ofloxacin is 400mg, and all the other are isotonic solution.
5. as claim 1 or 2 or 3 or 4 described composite collagen eye drops, it is characterized in that: described antibiotic is an ofloxacin.
6. as claim 1 or 2 or 3 or 4 described composite collagen eye drops, it is characterized in that: described isotonic solution is 5% glucose solution.
7. the preparation method of a composite collagen eye drops, it is characterized in that: the concrete making step of this method is:
(1) puts to death rat → get rat afterbody → clean → sterilization;
(2) aseptic condition separates down musculus caudalis tendon → distilled water flushing tendon → acetic acid or hydrochloric acid acid molten → pepsin or papain enzymolysis → saltout → water dialysis → collagen liquid.
(3) the antibiotic ofloxacin is added collagen liquid, mix homogeneously is made the composite collagen eye drops agent;
(4) sterile working is advanced the composite collagen eye drops fill in the eye-drop liquid bottle of strict sterilization, seals, and makes bottled composite collagen eye drops.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100984251A CN100381169C (en) | 2005-09-08 | 2005-09-08 | Composite collagen eye drops |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100984251A CN100381169C (en) | 2005-09-08 | 2005-09-08 | Composite collagen eye drops |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1927392A CN1927392A (en) | 2007-03-14 |
| CN100381169C true CN100381169C (en) | 2008-04-16 |
Family
ID=37857623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100984251A Active CN100381169C (en) | 2005-09-08 | 2005-09-08 | Composite collagen eye drops |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100381169C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090131303A1 (en) * | 2007-11-16 | 2009-05-21 | Bor-Shyue Hong | Methods and compositions for treating dry eye |
| CN101648004B (en) * | 2008-08-13 | 2013-11-06 | 北京和润创新医药科技发展有限公司 | Medicinal composition for treating eye diseases and application thereof |
| CN102210856B (en) * | 2011-06-02 | 2012-10-03 | 陕西巨子生物技术有限公司 | Collagen eye drops and preparation method thereof |
| CN105985429A (en) * | 2015-02-09 | 2016-10-05 | 广州创尔生物技术股份有限公司 | Aseptic collagen liquid with biological activity and preparation method thereof |
| CN111420036A (en) * | 2020-04-30 | 2020-07-17 | 广州市醒目医药科技有限公司 | Compound containing type I collagen and salvia miltiorrhiza extract, preparation and application |
| CN113713086A (en) * | 2021-08-20 | 2021-11-30 | 山西锦波生物医药股份有限公司 | Composition containing recombinant III-type humanized collagen and preparation method and application thereof |
| CN116726151B (en) * | 2023-03-13 | 2024-04-09 | 河北纳科生物科技有限公司 | Daily throwing eye drops for cornea damage repair and preparation method thereof |
-
2005
- 2005-09-08 CN CNB2005100984251A patent/CN100381169C/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Collagen shields dilivery of metilmicin： a study of ocular pharamacokineitics .. Dorigo,M T,et.CHEMOTHERAPY,Vol.41 No.1. 1995 * |
| 胶原蛋白在临床医学中的应用. 刘慧玲等.北京生物医学工程，第24卷第3期. 2005 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1927392A (en) | 2007-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100381169C (en) | Composite collagen eye drops | |
| US10383796B2 (en) | Application and uses of PRG4 and therapeutic modulation thereof | |
| US5079236A (en) | Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use | |
| JP2611159B2 (en) | Hyaluronic acid pharmacologically active fraction, method for producing the same and pharmaceutical composition | |
| US20020172712A1 (en) | Antiemetic, anti-motion sustained release drug delivery system | |
| CN101554369B (en) | External spraying agent and eye drop of compound oil nano-emulsion as well as preparation method thereof | |
| NO346214B1 (en) | Ophthalmic compositions and procedures for the treatment of eyes | |
| AU2005309555A1 (en) | Triple natural polymer viscoelastic composition | |
| Tabor et al. | Corneal damage due to eye contact with chlorhexidine gluconate | |
| CN102579334A (en) | Nasal drops containing sodium hyaluronate and preparation method thereof | |
| WO2016011498A1 (en) | Compositions and methods of use | |
| CN104906029A (en) | Nasal cavity preparation and preparing method and application thereof | |
| CN1927391A (en) | Collagen eye drops | |
| CN102188695B (en) | Ophthalmic gel composition | |
| CN102579492A (en) | Sodium hyaluronate eyedrop containing deproteinized calf blood extractive and preparation method thereof | |
| US20230146680A1 (en) | Method for producing enhanced anti-inflammatory / anti-catabolic agents from autologous physiological fluid | |
| CN105982911A (en) | Preparation method of high-viscoelasticity injection composed of glucosamine and sodium hyaluronate | |
| KR100963611B1 (en) | Eye composition comprising alginic acid based compounds and method of preparing the same | |
| US20150290248A1 (en) | Fibrous component for health, performance, and aesthetic treatment | |
| CN107802597B (en) | Sodium hyaluronate composition and preparation method and application thereof | |
| CN111000974B (en) | Rabbit milk active small peptide solution and extraction method and application thereof | |
| CN107296954A (en) | A kind of laminin Wound surface protection film | |
| CN114158724A (en) | A liquid functional food prepared from water | |
| Emam et al. | Autologous PRP Usage as a Mono Therapy for the Treatment of Moderate to Severe DED | |
| CN105214092B (en) | RHuIL-1Ra and combinations thereof and medicinal usage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Guangzhou Trauer Biotechnology Co., Ltd. Assignor: Tong Gang Contract fulfillment period: 2008.10.18 to 2014.10.18 contract change Contract record no.: 2009440001709 Denomination of invention: Composite collagen eye drops Granted publication date: 20080416 License type: Exclusive license Record date: 20091023 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.10.18 TO 2014.10.18; CHANGE OF CONTRACT Name of requester: GUANGZHOU TRAUER BIOISYSTECH CO., LTD. Effective date: 20091023 |
|
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU TRAUER BIOTECHNOLOGY CO.,LTD Free format text: FORMER OWNER: TONG GANG Effective date: 20100722 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510663 4/F, BUILDING A, NO.17, XIANGSHAN ROAD, SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY, GUANGDONG PROVINCE TO: 510663 NO.1, 4/F, BUILDING 17, XIANGSHAN ROAD, GUANGZHOU HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100722 Address after: 510663, No. 4, No. 17, Xiangshan Road, 1 hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee after: Guangzhou Trauer Biotechnology Co., Ltd. Address before: 4 building, A building, No. 17 Xiangshan Road, Luogang District Science City, Guangdong, Guangzhou 510663, China Patentee before: Tong Gang |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 510663, No. 4, No. 17, Xiangshan Road, 1 hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee after: Guangzhou Trauer Biotechnology Co., Ltd. Address before: 510663, No. 4, No. 17, Xiangshan Road, 1 hi tech Industrial Development Zone, Guangdong, Guangzhou Patentee before: Guangzhou Trauer Biotechnology Co., Ltd. |